Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements (Narrative) (Details)

v3.23.1
Fair Value Measurements (Narrative) (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Dec. 31, 2022
USD ($)
Y
Dec. 16, 2022
USD ($)
Y
Oct. 11, 2022
USD ($)
item
$ / shares
shares
Nov. 16, 2021
$ / shares
shares
Oct. 05, 2021
USD ($)
Jun. 29, 2021
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2022
USD ($)
Y
Dec. 31, 2021
USD ($)
shares
Jun. 30, 2021
Y
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Loss on common stock warrant liabilities               $ (1,129) $ 447  
Common stock, value $ 110             110 101  
Common stock warrant liabilities 13,869             13,869 0  
Proceeds from issuance of common stock for at-the-market offering, net               6,053 9,085  
Checkpoint Common Stock Warrants                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Fair value of warrants   $ 7,900                
Common stock warrant liabilities 11,170             11,170    
Checkpoint Common Stock Warrants | Common Stock and Pre-funded Warrants                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Net proceeds   0                
Checkpoint Common Stock Warrants | 2022 Director Offering                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Sale of stock, net proceeds   6,700                
Avenue                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Issuance of Warrants     $ 8,278              
Common stock warrant liabilities     $ 2,609              
Shares issued | shares     3,636,365              
Number of common stock (in units) | item     1              
Number of warrants (in units) | item     1              
Number of shares called by warrants | shares     1              
Warrants issued | shares     545,454              
Proceeds from issuance of common stock for at-the-market offering, net     $ 10,300              
Avenue | Pre funded warrants                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Number of warrants (in units) | item     1              
Number of shares called by warrants | shares     1              
Exercise price of warrants | $ / shares     $ 0.0001              
Unit Price Per Share | $ / shares     $ 3.2999              
Avenue | Common Stock and Pre-funded Warrants                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Number of warrants (in units) | item     1              
Unit Price Per Share | $ / shares     $ 3.30              
Caelum | AstraZeneca [Member]                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Percentage of proceeds from option exercise         42.40%   42.40%      
Option exercise price         $ 150,000   $ 150,000      
Proceeds from option exercise         $ 56,900   $ 56,900      
Journey | Dr. Reddy's Laboratories, Ltd [Member]                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Stock offering, price per share | $ / shares       $ 9.1721            
Stock offering, number of shares issued | shares       545,131            
Journey | Dr. Reddy's Laboratories, Ltd [Member] | Discount rate                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Warrant liability, measurement input                   0.30
Journey | Dr. Reddy's Laboratories, Ltd [Member] | Contingent Conditions are Met [Member]                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Minimum market capitalization for contingent payment           $ 150,000        
Common stock, value           5,000        
Contingent cash payment           $ 5,000        
Journey | Minimum | Dr. Reddy's Laboratories, Ltd [Member] | Expected life of the options to convert                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Warrant liability, measurement input | Y                   3
Journey | Maximum | Dr. Reddy's Laboratories, Ltd [Member] | Expected life of the options to convert                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Warrant liability, measurement input | Y                   5
Common Stock Warrant | Checkpoint Common Stock Warrants                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Issuance of Warrants               7,640    
Loss on common stock warrant liabilities $ 3,300 (1,200)           3,252    
Net proceeds   $ 6,700                
Common Stock Warrant | Avenue                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Issuance of Warrants               8,278    
Loss on common stock warrant liabilities     $ (5,669)         (5,669)    
Placement Agent Warrants | Checkpoint Common Stock Warrants                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Issuance of Warrants               $ 278    
Placement Agent Warrants | Checkpoint Common Stock Warrants | Expected life of the options to convert                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Warrant liability, measurement input | Y 5.0 5.0           5.0    
Placement Agent Warrants | Urica                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Issuance of Warrants               $ 90    
Placement Agent Warrants | Journey                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Issuance of Warrants                 $ 362  
Percentage of common stock for which the Preferred A is exchanged                 5.00%  
Warrant expiration term                 5 years  
Number of shares issued related to the conversion of warrants | shares                 111,567  
Contingent Payment Warrants                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Loss on common stock warrant liabilities                 $ 447  
Contingent Payment Warrants | Urica                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Common stock warrant liabilities $ 100             $ 100 0  
Contingent Payment Warrants | Journey                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Issuance of Warrants                 $ 3,819